This invention is related to compounds of general formula (I) wherein X isoxygen or sulphur or a NR7 group； R1 is C3-C8 alkyl, or C1-C8 alkylsubstituted by phenoxy or phenyl, both phenoxy or phenyl being optionallysubstituted by one or more fluoro, chloro, trifluoromethyl, C1-C6 alkyl,hydroxyl, C1-C6 alkoxy； R2, R3 are independently hydrogen, C1-C6 alkyl,halogen, trifluoromethyl, hydroxy or C1-C6 alkoxy； R4 is hydrogen, C1-C8alkyl； R5, R6 are independently hydrogen, C1-C3 alkyl, optionally substitutedby hydroxy or phenyl； R7 is hydrogen or straight or branched C1-C3 alkyl； Hetis a five to seven membered, saturated or unsaturated heteromonocyclic or aneight to ten membered, saturated or unsaturated heterobicyclic group,containing one or more heteroatoms chosen independently from nitrogen, oxygenand sulphur, said mono- or bicyclic groups being optionally substituted by C1-C6alkyl, halogen, hydroxyl or C1-C6 alkoxy； and the pharmaceuticallyacceptable salts or prodrug thereof, that are active as sodium and/or calciumchannel modulators and/or as selective MAO-B inhibitors and therefore usefulin preventing, alleviating and curing a wide range of pathologies, including,but not limited to, neurological, psychiatric, cardiovascular, inflammatory,ophthalmic, urologic, metabolic and gastrointestinal diseases, where the abovemechanisms have been described as playing a pathological role.
